Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of monthly degarelix in prostate cancer
2006-006913-34Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Feb 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of degarelix in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Primary endpoint: Long-term clinical safety and tolerability of degarelix. Started Feb 2007; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-006913-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006913-34.